Pharmacy Leadership Amid the Pandemic: Maintaining Patient Safety During Uncertain Times

Author:

Derrong Lin Irene1,Hertig John B.2ORCID

Affiliation:

1. Purdue University, West Lafayette, IN, USA

2. Butler University, Indianapolis, IN, USA

Abstract

The relentless surges of global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that caused the Covid-19 disease had pressured researchers and regulators to develop effective treatments quickly. While studying these therapies amid the pandemic, threats to patient care were reported, including (1) maintaining adequate safeguards as clinical effectiveness and safety data evolves, (2) risks from online counterfeit medications, and (3) disruption of the global pharmaceutical supply chain. This article discusses these patient safety threats and suggests strategies that promote patient safety, foster medication intelligence, and mitigate drug shortages. As the world continues to develop safe and effective treatments for Covid-19, patient safety is paramount. In response to the World Health Organization (WHO) Global Safety Challenge: Medication Without Harm, leaders must establish effective approaches to improve medication safety during the pandemic. Successfully integrating these leadership strategies with current practices allows pharmacy leaders to implement robust systems to reduce errors, prevent harm, and advocate for patient safety.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Reference24 articles.

1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020. Accessed May 23, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

2. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases in US. 2020. Accessed May 23, 2021. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

3. Drug Evaluation during the Covid-19 Pandemic

4. Correction to: Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety

5. On Patient Safety: COVID-19 Exposes the Dangerous State of Drug and Device Supply Chains

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Global Followership Models and Practices Within Healthcare Settings;Handbook of Global Leadership and Followership;2023

2. Global Followership Models and Practices Within Healthcare Settings;Handbook of Global Leadership and Followership;2023

3. Prioritization of Risks in the Pharmaceutical Supply Chains: TOPSIS Approach;Flexible Systems Management;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3